BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 32914125)

  • 1. Piceatannol attenuates fat accumulation and oxidative stress in steatosis-induced HepG2 cells.
    Yang JS; Tongson J; Kim KH; Park Y
    Curr Res Food Sci; 2020 Nov; 3():92-99. PubMed ID: 32914125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
    Hsu WH; Chen TH; Lee BH; Hsu YW; Pan TM
    Food Chem Toxicol; 2014 Feb; 64():94-103. PubMed ID: 24275089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Free radical biology for medicine: learning from nonalcoholic fatty liver disease.
    Serviddio G; Bellanti F; Vendemiale G
    Free Radic Biol Med; 2013 Dec; 65():952-968. PubMed ID: 23994574
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Park M; Yoo JH; Lee YS; Lee HJ
    Nutrients; 2019 Feb; 11(3):. PubMed ID: 30813654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxymatrine attenuates hepatic steatosis in non-alcoholic fatty liver disease rats fed with high fructose diet through inhibition of sterol regulatory element binding transcription factor 1 (Srebf1) and activation of peroxisome proliferator activated receptor alpha (Pparα).
    Shi LJ; Shi L; Song GY; Zhang HF; Hu ZJ; Wang C; Zhang DH
    Eur J Pharmacol; 2013 Aug; 714(1-3):89-95. PubMed ID: 23791610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zinc-α2-glycoprotein 1 attenuates non-alcoholic fatty liver disease by negatively regulating tumour necrosis factor-α.
    Liu T; Luo X; Li ZH; Wu JC; Luo SZ; Xu MY
    World J Gastroenterol; 2019 Sep; 25(36):5451-5468. PubMed ID: 31576092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of herbal composition Gambigyeongsinhwan (4) on hepatic steatosis and inflammation in Otsuka Long-Evans Tokushima fatty rats and HepG2 cells.
    Yoon S; Kim J; Lee H; Lee H; Lim J; Yang H; Shin SS; Yoon M
    J Ethnopharmacol; 2017 Jan; 195():204-213. PubMed ID: 27845265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alisol A 24-Acetate Prevents Hepatic Steatosis and Metabolic Disorders in HepG2 Cells.
    Zeng L; Tang W; Yin J; Feng L; Li Y; Yao X; Zhou B
    Cell Physiol Biochem; 2016; 40(3-4):453-464. PubMed ID: 27889747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lycopus lucidus Turcz. ex Benth. Attenuates free fatty acid-induced steatosis in HepG2 cells and non-alcoholic fatty liver disease in high-fat diet-induced obese mice.
    Lee MR; Yang HJ; Park KI; Ma JY
    Phytomedicine; 2019 Mar; 55():14-22. PubMed ID: 30668424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of
    Mun J; Park J; Yoon HG; You Y; Choi KC; Lee YH; Kim K; Lee J; Kim OK; Jun W
    J Med Food; 2019 Dec; 22(12):1262-1270. PubMed ID: 31834842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Silibinin ameliorates hepatic lipid accumulation and oxidative stress in mice with non-alcoholic steatohepatitis by regulating CFLAR-JNK pathway.
    Liu Y; Xu W; Zhai T; You J; Chen Y
    Acta Pharm Sin B; 2019 Jul; 9(4):745-757. PubMed ID: 31384535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LB100 ameliorates nonalcoholic fatty liver disease
    Chen XY; Cai CZ; Yu ML; Feng ZM; Zhang YW; Liu PH; Zeng H; Yu CH
    World J Gastroenterol; 2019 Dec; 25(45):6607-6618. PubMed ID: 31832001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. n-3 Polyunsaturated fatty acids for the management of alcoholic liver disease: A critical review.
    Wang M; Ma LJ; Yang Y; Xiao Z; Wan JB
    Crit Rev Food Sci Nutr; 2019; 59(sup1):S116-S129. PubMed ID: 30580553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of hepassocin in the development of non-alcoholic fatty liver disease.
    Wu HT; Lu FH; Ou HY; Su YC; Hung HC; Wu JS; Yang YC; Wu CL; Chang CJ
    J Hepatol; 2013 Nov; 59(5):1065-72. PubMed ID: 23792031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoxia exacerbates nonalcoholic fatty liver disease via the HIF-2α/PPARα pathway.
    Chen J; Chen J; Fu H; Li Y; Wang L; Luo S; Lu H
    Am J Physiol Endocrinol Metab; 2019 Oct; 317(4):E710-E722. PubMed ID: 31430204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coenzyme Q10 attenuates high-fat diet-induced non-alcoholic fatty liver disease through activation of the AMPK pathway.
    Chen K; Chen X; Xue H; Zhang P; Fang W; Chen X; Ling W
    Food Funct; 2019 Feb; 10(2):814-823. PubMed ID: 30675881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crocin ameliorates hepatic steatosis through activation of AMPK signaling in db/db mice.
    Luo L; Fang K; Dan X; Gu M
    Lipids Health Dis; 2019 Jan; 18(1):11. PubMed ID: 30621686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resolvin D1 reduces ER stress-induced apoptosis and triglyceride accumulation through JNK pathway in HepG2 cells.
    Jung TW; Hwang HJ; Hong HC; Choi HY; Yoo HJ; Baik SH; Choi KM
    Mol Cell Endocrinol; 2014 Jun; 391(1-2):30-40. PubMed ID: 24784707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-Alcoholic Fatty Liver Disease.
    Engin A
    Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dietary α-lactalbumin induced fatty liver by enhancing nuclear liver X receptor αβ/sterol regulatory element-binding protein-1c/PPARγ expression and minimising PPARα/carnitine palmitoyltransferase-1 expression and AMP-activated protein kinase α phosphorylation associated with atherogenic dyslipidaemia, insulin resistance and oxidative stress in Balb/c mice.
    López-Oliva ME; Garcimartin A; Muñoz-Martínez E
    Br J Nutr; 2017 Dec; 118(11):914-929. PubMed ID: 29173234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.